Dare Bioscience, Inc. (DARE)
NASDAQ
Key stats Fiscal year 2025
Income statement
- Revenue
- 1,030,193 10429.4%
- Net income
- -13,400,000
- Operating income
- -13,552,334
- Earnings per share
- -1.20
- R&D expense
- 5,523,352
Growth and profitability
- Operating margin
- -1,315.51
- Net margin
- -1,300.73
- Return on equity
- -471.39
- Return on assets
- -41.26
- Free cash flow margin
- -997.01
Balance sheet
- Total assets
- 32,474,563
- Total liabilities
- 29,631,929
- Shareholders' equity
- 2,842,634
- Cash and equivalents
- 24,711,356
- Current ratio
- 1.14
Cash flow and ratios
- Operating cash flow
- -9,885,870
- Free cash flow
- -10,271,148
Shareholder returns
- Shares outstanding
- 15,289,502
- Book value per share
- 0.19
Company information
- Headquarters
- San Diego, CA
- Exchange
- NASDAQ
- Fiscal year end
- 12-31
- Industry (SEC)
- Pharmaceutical Preparations
Fiscal year end: · Source: SEC EDGAR
Dare Bioscience, Inc. trades on NASDAQ under the ticker symbol DARE. This page brings together its price chart, company profile, key financial figures and technical indicators.